Updated on 2021/09/02

写真a

 
SATO Yoshitaka
 
Organization
Graduate School of Medicine Program in Integrated Medicine Microbiology and Immunology Lecturer
Graduate School
Graduate School of Medicine
Undergraduate School
School of Medicine Department of Medicine
Title
Lecturer

Degree 2

  1. 博士(医学) ( 2013.6   名古屋大学 ) 

  2. 修士(工学) ( 2006.3   名古屋大学 ) 

Research History 7

  1. MEXT

    2021.8

  2. JST   さきがけ研究者(兼任)

    2019.10

      More details

    Country:Japan

  3. 名古屋大学大学院   医学系研究科 微生物免疫学講座 ウイルス学   助教

    2015.7

      More details

    Country:Japan

  4. Nagoya University   Nagoya University Hospital Center of National University Hospital for Infection Control

    2015.4

  5. 名古屋大学大学院   医学系研究科 附属医学教育研究支援センター   特任助教

    2015.4 - 2015.6

      More details

    Country:Japan

  6. 名古屋大学医学部附属病院   初期研修医

    2013.4 - 2015.3

      More details

    Country:Japan

  7. 日本学術振興会 特別研究員DC1

    2007.4 - 2009.3

      More details

    Country:Japan

▼display all

Education 4

  1. Nagoya University   Graduate School, Division of Medical Sciences

    - 2013.6

      More details

    Country: Japan

  2. Kobe University   Faculty of Medicine

    - 2013.3

      More details

    Country: Japan

  3. Nagoya University   Graduate School, Division of Engineering

    - 2006.3

      More details

    Country: Japan

  4. Nagoya University   Faculty of Engineering

    - 2004.3

      More details

    Country: Japan

Professional Memberships 5

  1. 日本ウイルス学会

  2. 日本癌学会

  3. 日本感染症学会

  4. 日本渡航医学会

  5. 日本臨床ウイルス学会

Committee Memberships 1

  1. 日本ウイルス学会   評議員  

    2018.9   

Awards 5

  1. 日本ウイルス学会 杉浦賞

    2019.10   日本ウイルス学会  

     More details

    Country:Japan

  2. 日本臨床ウイルス学会 若手奨励賞

    2019.5   日本臨床ウイルス学会  

     More details

    Award type:Award from Japanese society, conference, symposium, etc.  Country:Japan

  3. Poster Prize at the 17th International Symposium on EBV and associated diseases

    2016.8  

     More details

    Award type:Award from international society, conference, symposium, etc.  Country:Switzerland

  4. 第12回EBウイルス研究会学術奨励賞

    2015.7   EBウイルス研究会  

     More details

    Country:Japan

  5. ASM travel grants

    2008.3  

     More details

    Award type:Award from international society, conference, symposium, etc.  Country:Japan

 

Papers 55

  1. Deletion of Viral microRNAs in the Oncogenesis of Epstein-Barr Virus-Associated Lymphoma

    Kimura Hiroshi, Okuno Yusuke, Sato Yoshitaka, Watanabe Takahiro, Murata Takayuki

    FRONTIERS IN MICROBIOLOGY   Vol. 12   page: 667968   2021.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.3389/fmicb.2021.667968

    Web of Science

    PubMed

  2. RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells

    Yanagi Yusuke, Okuno Yusuke, Narita Yohei, Al Masud H. M. Abdullah, Watanabe Takahiro, Sato Yoshitaka, Kanda Teru, Kimura Hiroshi, Murata Takayuki

    VIROLOGY   Vol. 557   page: 44 - 54   2021.5

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.virol.2021.02.004

    Web of Science

    PubMed

  3. A Case Report of Bursitis, Bacteremia, and Disseminated Infection of Mycobacteroides (Mycobacterium) abscessus subsp. massiliense.

    Oka K, Morioka H, Eguchi M, Sato Y, Tetsuka N, Iguchi M, Kanematsu T, Fukano H, Hoshino Y, Kiyoi H, Yagi T

    Internal medicine (Tokyo, Japan)     2021.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.2169/internalmedicine.6189-20

    PubMed

  4. Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma

    Takano Gaku, Esaki Shinichi, Goshima Fumi, Enomoto Atsushi, Hatano Yoshimi, Ozaki Haruka, Watanabe Takahiro, Sato Yoshitaka, Kawakita Daisuke, Murakami Shingo, Murata Takayuki, Nishiyama Yukihiro, Iwasaki Shinichi, Kimura Hiroshi

    MOLECULAR THERAPY-ONCOLYTICS   Vol. 20   page: 220 - 227   2021.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.omto.2020.12.007

    Web of Science

    PubMed

  5. Role of Epstein-Barr Virus C Promoter Deletion in Diffuse Large B Cell Lymphoma

    Mabuchi Seiyo, Hijioka Fumiya, Watanabe Takahiro, Yanagi Yusuke, Okuno Yusuke, Al Masud H. M. Abdullah, Sato Yoshitaka, Murata Takayuki, Kimura Hiroshi

    CANCERS   Vol. 13 ( 3 )   2021.2

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.3390/cancers13030561

    Web of Science

    PubMed

  6. Anti-tumor effect of IL2-expressing HSV amplicon vector and oncolytic virus HF10

    Esaki Shinichi, Goshima Fumi, Takano Gaku, Watanabe Takahiro, Sato Yoshitaka, Murata Takayuki, Kimura Hiroshi

    CANCER SCIENCE   Vol. 112   page: 394 - 394   2021.2

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Web of Science

  7. Direct Evidence of Abortive Lytic Infection-Mediated Establishment of Epstein-Barr Virus Latency During B-Cell Infection

    Inagaki Tomoki, Sato Yoshitaka, Ito Jumpei, Takaki Mitsuaki, Okuno Yusuke, Yaguchi Masahiro, Al Masud H. M. Abdullah, Watanabe Takahiro, Sato Kei, Iwami Shingo, Murata Takayuki, Kimura Hiroshi

    FRONTIERS IN MICROBIOLOGY   Vol. 11   page: 575255   2021.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.3389/fmicb.2020.575255

    Web of Science

    PubMed

  8. Oncolytic activity of HF10 in head and neck squamous cell carcinomas.

    Esaki S, Goshima F, Ozaki H, Takano G, Hatano Y, Kawakita D, Ijichi K, Watanabe T, Sato Y, Murata T, Iwata H, Shibamoto Y, Murakami S, Nishiyama Y, Kimura H

    Cancer gene therapy   Vol. 27 ( 7-8 ) page: 585 - 598   2020.8

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41417-019-0129-3

    Web of Science

    PubMed

  9. Number of concomitant drugs with thrombocytopenic adverse effects and the extent inflammatory response resolution are risk factors for thrombocytopenia in patients treated with linezolid for more than 14 days

    Sato Yoshitaka, Iguchi Mitsutaka, Kato Yoshiaki, Morioka Hiroshi, Hirabayashi Aki, Tetsuka Nobuyuki, Tomita Yuka, Kato Daizo, Yamada Kiyofumi, Kimura Hiroshi, Yagi Tetsuya

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 82 ( 3 ) page: 407 - 414   2020.8

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.18999/nagjms.82.3.407

    Web of Science

    PubMed

  10. Oncogenesis of CAEBV revealed: Intragenic deletions in the viral genome and leaky expression of lytic genes

    Murata Takayuki, Okuno Yusuke, Sato Yoshitaka, Watanabe Takahiro, Kimura Hiroshi

    REVIEWS IN MEDICAL VIROLOGY   Vol. 30 ( 2 ) page: e2095   2020.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/rmv.2095

    Web of Science

    PubMed

  11. Antitumor activity of cyclin-dependent kinase inhibitor alsterpaullone in Epstein-Barr virus-associated lymphoproliferative disorders

    Watanabe Takahiro, Sato Yoshitaka, Al Masud H. M. Abdullah, Takayama Masahiro, Matsuda Hiroki, Hara Yuya, Yanagi Yusuke, Yoshida Masahiro, Goshima Fumi, Murata Takayuki, Kimura Hiroshi

    CANCER SCIENCE   Vol. 111 ( 1 ) page: 279 - 287   2020.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.14241

    Web of Science

    PubMed

  12. [Dynamic changes of cellular environment during Epstein-Barr virus productive replication].

    Sato Y

    Uirusu   Vol. 70 ( 1 ) page: 83 - 90   2020

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.2222/jsv.70.83

    PubMed

  13. Epstein-Barr Virus BBRF2 Is Required for Maximum Infectivity

    Al Masud H. M. Abdullah, Yanagi Yusuke, Watanabe Takahiro, Sato Yoshitaka, Kimura Hiroshi, Murata Takayuki

    MICROORGANISMS   Vol. 7 ( 12 )   2019.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3390/microorganisms7120705

    Web of Science

    PubMed

  14. Initial Characterization of the Epstein-Barr Virus BSRF1 Gene Product

    Yanagi Yusuke, Al Masud H. M. Abdullah, Watanabe Takahiro, Sato Yoshitaka, Goshima Fumi, Kimura Hiroshi, Murata Takayuki

    VIRUSES-BASEL   Vol. 11 ( 3 )   2019.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3390/v11030285

    Web of Science

    PubMed

  15. Publisher Correction: Defective Epstein-Barr virus in chronic active infection and haematological malignancy.

    Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, Okuno T, Murakami N, Yoshida K, Sawada A, Inoue M, Kawa K, Seto M, Ohshima K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Narita Y, Yoshida M, Goshima F, Kawada JI, Nishida T, Kiyoi H, Kato S, Nakamura S, Morishima S, Yoshikawa T, Fujiwara S, Shimizu N, Isobe Y, Noguchi M, Kikuta A, Iwatsuki K, Takahashi Y, Kojima S, Ogawa S, Kimura H

    Nature microbiology   Vol. 4 ( 3 ) page: 544   2019.3

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41564-019-0387-8

    PubMed

  16. The BOLF1 gene is necessary for effective Epstein-Barr viral infectivity.

    Masud HMAA, Watanabe T, Sato Y, Goshima F, Kimura H, Murata T

    Virology   Vol. 531   page: 114-125   2019.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.virol.2019.02.015

    PubMed

  17. S-like phase CDKs stabilize the Epstein-Barr virus BDLF4 protein to temporally control late gene transcription.

    Sato Y, Watanabe T, Suzuki C, Abe Y, Masud HMAA, Inagaki T, Yoshida M, Suzuki T, Goshima F, Adachi J, Tomonaga T, Murata T, Kimura H

    Journal of virology     2019.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1128/JVI.01707-18

    PubMed

  18. Defective Epstein-Barr virus in chronic active infection and haematological malignancy.

    Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, Okuno T, Murakami N, Yoshida K, Sawada A, Inoue M, Kawa K, Seto M, Ohshima K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Narita Y, Yoshida M, Goshima F, Kawada JI, Nishida T, Kiyoi H, Kato S, Nakamura S, Morishima S, Yoshikawa T, Fujiwara S, Shimizu N, Isobe Y, Noguchi M, Kikuta A, Iwatsuki K, Takahashi Y, Kojima S, Ogawa S, Kimura H

    Nature microbiology     2019.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41564-018-0334-0

    PubMed

  19. Challenges in Managing EBV-Associated T- and NK-Cell Lymphoproliferative Diseases

    Sato Yoshitaka

    FRONTIERS IN PEDIATRICS   Vol. 6   page: 320   2018.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3389/fped.2018.00320

    Web of Science

    PubMed

  20. Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells.

    Kawada JI, Ando S, Torii Y, Watanabe T, Sato Y, Ito Y, Kimura H

    Cancer medicine     2018.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/cam4.1311

    PubMed

  21. BGLF2 Increases Infectivity of Epstein-Barr Virus by Activating AP-1 upon De Novo Infection

    Konishi Natsuno, Narita Yohei, Hijioka Fumiya, Al Masud H. M. Abdullah, Sato Yoshitaka, Kimura Hiroshi, Murata Takayuki

    MSPHERE   Vol. 3 ( 2 )   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1128/mSphere.00138-18

    Web of Science

    PubMed

  22. Regulation of Epstein-Barr Virus Life Cycle and Cell Proliferation by Histone H3K27 Methyltransferase EZH2 in Akata Cells

    Ichikawa Takaya, Okuno Yusuke, Sato Yoshitaka, Goshima Fumi, Yoshiyama Hironori, Kanda Teru, Kimura Hiroshi, Murata Takayuki

    MSPHERE   Vol. 3 ( 6 )   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1128/mSphere.00478-18

    Web of Science

    PubMed

  23. Epstein-Barr Virus BKRF4 Gene Product Is Required for Efficient Progeny Production. Reviewed

    Masud HMAA, Watanabe T, Yoshida M, Sato Y, Goshima F, Kimura H, Murata T

    Journal of virology   Vol. 91 ( 23 )   2017.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1128/JVI.00975-17

    PubMed

  24. The Epstein-Barr Virus BRRF1 Gene Is Dispensable for Viral Replication in HEK293 cells and Transformation. Reviewed

    Yoshida M, Watanabe T, Narita Y, Sato Y, Goshima F, Kimura H, Murata T

    Scientific reports   Vol. 7 ( 1 ) page: 6044   2017.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41598-017-06413-7

    PubMed

  25. Elimination of LMP1-expressing cells from a monolayer of gastric cancer AGS cells. Reviewed

    Sato Y, Ochiai S, Murata T, Kanda T, Goshima F, Kimura H

    Oncotarget     2017.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.18632/oncotarget.16996

    PubMed

  26. The C-Terminus of Epstein-Barr Virus BRRF2 Is Required for its Proper Localization and Efficient Virus Production. Reviewed

    Watanabe T, Sakaida K, Yoshida M, Masud HM, Sato Y, Goshima F, Kimura H, Murata T

    Frontiers in microbiology   Vol. 8   page: 125   2017

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3389/fmicb.2017.00125

    PubMed

  27. The efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model.

    Tanaka R, Goshima F, Esaki S, Sato Y, Murata T, Nishiyama Y, Watanabe D, Kimura H

    American journal of cancer research   Vol. 7 ( 8 ) page: 1693 - 1703   2017

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PubMed

  28. Characterization of a Suppressive <i>Cis</i>-acting Element in the Epstein-Barr Virus LMP1 Promoter. Reviewed

    Yoshida M, Murata T, Ashio K, Narita Y, Watanabe T, Masud HMAA, Sato Y, Goshima F, Kimura H

    Frontiers in microbiology   Vol. 8   page: 2302   2017

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3389/fmicb.2017.02302

    PubMed

  29. The efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model

    Tanaka Rui, Goshima Fumi, Esaki Shinichi, Sato Yoshitaka, Murata Takayuki, Nishiyama Yukihiro, Watanabe Daisuke, Kimura Hiroshi

    AMERICAN JOURNAL OF CANCER RESEARCH   Vol. 7 ( 8 ) page: 1693-1703   2017

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  30. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. Reviewed

    Ando S, Kawada JI, Watanabe T, Suzuki M, Sato Y, Torii Y, Asai M, Goshima F, Murata T, Shimizu N, Ito Y, Kimura H

    Oncotarget   Vol. 7 ( 47 ) page: 76793-76805   2016.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.18632/oncotarget.12529

    PubMed

  31. Induction of Epstein-Barr Virus Oncoprotein LMP1 by Transcription Factors AP-2 and Early B Cell Factor. Reviewed

    Murata T, Noda C, Narita Y, Watanabe T, Yoshida M, Ashio K, Sato Y, Goshima F, Kanda T, Yoshiyama H, Tsurumi T, Kimura H

    Journal of virology   Vol. 90 ( 8 ) page: 3873-89   2016.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1128/JVI.03227-15

    PubMed

  32. Induction of Epstein-Barr Virus Oncoprotein Latent Membrane Protein 1 (LMP1) by Transcription Factors Activating Protein 2 (AP-2) and Early B Cell Factor (EBF) Reviewed

    Takayuki Murata, Chieko Noda, Yohei Narita, Takahiro Watanabe, Masahiro Yoshida, Keiji Ashio, Yoshitaka Sato, Fumi Goshima, Teru Kanda, Hironori Yoshiyama, Tatsuya Tsurumi, and Hiroshi Kimura

    Journal of Virology   Vol. 90   page: 3873-3889   2016

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  33. The Epstein-Barr Virus BDLF4 Gene Is Required for Efficient Expression of Viral Late Lytic Genes. Reviewed

    Watanabe T, Narita Y, Yoshida M, Sato Y, Goshima F, Kimura H, Murata T

    Journal of virology   Vol. 89 ( 19 ) page: 10120-4   2015.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1128/JVI.01604-15

    PubMed

  34. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases. Reviewed

    Kanazawa T, Hiramatsu Y, Iwata S, Siddiquey M, Sato Y, Suzuki M, Ito Y, Goshima F, Murata T, Kimura H

    Clinical cancer research : an official journal of the American Association for Cancer Research   Vol. 20 ( 19 ) page: 5075-84   2014.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1158/1078-0432.CCR-14-0580

    PubMed

  35. Role of latent membrane protein 1 in chronic active Epstein-Barr virus infection-derived T/NK-cell proliferation. Reviewed

    Ito T, Kawazu H, Murata T, Iwata S, Arakawa S, Sato Y, Kuzushima K, Goshima F, Kimura H

    Cancer medicine   Vol. 3 ( 4 ) page: 787-95   2014.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/cam4.256

    PubMed

  36. Modes of infection and oncogenesis by the Epstein-Barr virus. Reviewed

    Murata T, Sato Y, Kimura H

    Reviews in medical virology   Vol. 24 ( 4 ) page: 242-53   2014.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/rmv.1786

    PubMed

  37. Genome guardian p53 and viral infections. Reviewed

    Sato Y, Tsurumi T

    Reviews in medical virology   Vol. 23 ( 4 ) page: 213-20   2013.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/rmv.1738

    PubMed

  38. Different distributions of Epstein-Barr virus early and late gene transcripts within viral replication compartments. Reviewed

    Sugimoto A, Sato Y, Kanda T, Murata T, Narita Y, Kawashima D, Kimura H, Tsurumi T

    Journal of virology   Vol. 87 ( 12 ) page: 6693-9   2013.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1128/JVI.00219-13

    PubMed

  39. Mitochondrial defect drives non-autonomous tumour progression through Hippo signalling in Drosophila. Reviewed

    Ohsawa S, Sato Y, Enomoto M, Nakamura M, Betsumiya A, Igaki T

    Nature   Vol. 490 ( 7421 ) page: 547-51   2012.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/nature11452

    PubMed

  40. Noise cancellation: viral fine tuning of the cellular environment for its own genome replication. Reviewed

    Sato Y, Tsurumi T

    PLoS pathogens   Vol. 6 ( 12 ) page: e1001158   2010.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1371/journal.ppat.1001158

    PubMed

  41. Transient increases in p53-responsible gene expression at early stages of Epstein-Barr virus productive replication. Reviewed

    Sato Y, Shirata N, Murata T, Nakasu S, Kudoh A, Iwahori S, Nakayama S, Chiba S, Isomura H, Kanda T, Tsurumi T

    Cell cycle (Georgetown, Tex.)   Vol. 9 ( 4 ) page: 807-14   2010.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PubMed

  42. Epstein-Barr virus polymerase processivity factor enhances BALF2 promoter transcription as a coactivator for the BZLF1 immediate-early protein. Invited Reviewed

    Nakayama S, Murata T, Murayama K, Yasui Y, Sato Y, Kudoh A, Iwahori S, Isomura H, Kanda T, Tsurumi T

    The Journal of biological chemistry   Vol. 284 ( 32 ) page: 21557-68   2009.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1074/jbc.M109.015685

    PubMed

  43. Phosphorylation of p27Kip1 by Epstein-Barr virus protein kinase induces its degradation through SCFSkp2 ubiquitin ligase actions during viral lytic replication. Reviewed

    Iwahori S, Murata T, Kudoh A, Sato Y, Nakayama S, Isomura H, Kanda T, Tsurumi T

    The Journal of biological chemistry   Vol. 284 ( 28 ) page: 18923-31   2009.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1074/jbc.M109.015123

    PubMed

  44. Degradation of phosphorylated p53 by viral protein-ECS E3 ligase complex. Reviewed

    Sato Y, Kamura T, Shirata N, Murata T, Kudoh A, Iwahori S, Nakayama S, Isomura H, Nishiyama Y, Tsurumi T

    PLoS pathogens   Vol. 5 ( 7 ) page: e1000530   2009.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1371/journal.ppat.1000530

    PubMed

  45. Homologous recombinational repair factors are recruited and loaded onto the viral DNA genome in Epstein-Barr virus replication compartments. Reviewed

    Kudoh A, Iwahori S, Sato Y, Nakayama S, Isomura H, Murata T, Tsurumi T

    Journal of virology   Vol. 83 ( 13 ) page: 6641-51   2009.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1128/JVI.00049-09

    PubMed

  46. Efficient production of infectious viruses requires enzymatic activity of Epstein-Barr virus protein kinase. Reviewed

    Murata T, Isomura H, Yamashita Y, Toyama S, Sato Y, Nakayama S, Kudoh A, Iwahori S, Kanda T, Tsurumi T

    Virology   Vol. 389 ( 1-2 ) page: 75-81   2009.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.virol.2009.04.007

    PubMed

  47. Expression of Epstein-Barr virus BZLF1 immediate-early protein induces p53 degradation independent of MDM2, leading to repression of p53-mediated transcription. Reviewed

    Sato Y, Shirata N, Kudoh A, Iwahori S, Nakayama S, Murata T, Isomura H, Nishiyama Y, Tsurumi T

    Virology   Vol. 388 ( 1 ) page: 204-11   2009.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.virol.2009.03.017

    PubMed

  48. TORC2, a coactivator of cAMP-response element-binding protein, promotes Epstein-Barr virus reactivation from latency through interaction with viral BZLF1 protein. Reviewed

    Murata T, Sato Y, Nakayama S, Kudoh A, Iwahori S, Isomura H, Tajima M, Hishiki T, Ohshima T, Hijikata M, Shimotohno K, Tsurumi T

    The Journal of biological chemistry   Vol. 284 ( 12 ) page: 8033-41   2009.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1074/jbc.M808466200

    PubMed

  49. Identification of phosphorylation sites on transcription factor Sp1 in response to DNA damage and its accumulation at damaged sites. Reviewed

    Iwahori S, Yasui Y, Kudoh A, Sato Y, Nakayama S, Murata T, Isomura H, Tsurumi T

    Cellular signalling   Vol. 20 ( 10 ) page: 1795-803   2008.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.cellsig.2008.06.007

    PubMed

  50. Noncanonical TATA sequence in the UL44 late promoter of human cytomegalovirus is required for the accumulation of late viral transcripts. Reviewed

    Isomura H, Stinski MF, Kudoh A, Murata T, Nakayama S, Sato Y, Iwahori S, Tsurumi T

    Journal of virology   Vol. 82 ( 4 ) page: 1638-46   2008.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1128/JVI.01917-07

    PubMed

  51. A cis element between the TATA Box and the transcription start site of the major immediate-early promoter of human cytomegalovirus determines efficiency of viral replication. Reviewed

    Isomura H, Stinski MF, Kudoh A, Nakayama S, Murata T, Sato Y, Iwahori S, Tsurumi T

    Journal of virology   Vol. 82 ( 2 ) page: 849-58   2008.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1128/JVI.01593-07

    PubMed

  52. Enhanced phosphorylation of transcription factor sp1 in response to herpes simplex virus type 1 infection is dependent on the ataxia telangiectasia-mutated protein. Reviewed

    Iwahori S, Shirata N, Kawaguchi Y, Weller SK, Sato Y, Kudoh A, Nakayama S, Isomura H, Tsurumi T

    Journal of virology   Vol. 81 ( 18 ) page: 9653-64   2007.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1128/JVI.00568-07

    PubMed

  53. The late promoter of the human cytomegalovirus viral DNA polymerase processivity factor has an impact on delayed early and late viral gene products but not on viral DNA synthesis. Reviewed

    Isomura H, Stinski MF, Kudoh A, Nakayama S, Iwahori S, Sato Y, Tsurumi T

    Journal of virology   Vol. 81 ( 12 ) page: 6197-206   2007.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1128/JVI.00089-07

    PubMed

  54. Sumoylation of CCAAT/enhancer-binding protein alpha and its functional roles in hepatocyte differentiation. Reviewed

    Sato Y, Miyake K, Kaneoka H, Iijima S

    The Journal of biological chemistry   Vol. 281 ( 31 ) page: 21629-39   2006.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1074/jbc.M600852200

    PubMed

  55. Identification of cis-acting regions that contribute to neuron-specific expression of the GAP-43 gene. Reviewed

    Takahashi M, Sato Y, Nakagami Y, Miyake K, Iijima S

    Bioscience, biotechnology, and biochemistry   Vol. 70 ( 6 ) page: 1492-5   2006.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1271/bbb.50576

    PubMed

▼display all

Research Project for Joint Research, Competitive Funding, etc. 7

  1. 内因性微粒子が駆動するウイル ス関連疾患の理解

    2019.10 - 2024.3

    さきがけ「生体における微粒子の機能と制御」領域 

      More details

    Grant type:Competitive

  2. EBV関連NK細胞性腫瘍における スーパーエンハンサーの解析

    2019.9 - 2021.3

    日米医学協力計画 若手・女性育成のための公募 

      More details

    Grant type:Competitive

  3. Epstein-Barrウイルス潜伏感染成立の分子基盤

    2018.7 - 2019.3

    研究助成 

      More details

    Grant type:Competitive

  4. 数理モデルと実験データの融合によるEpstein-Barrウイルス感染のモニタリング

    2018.5 - 2019.9

    研究助成 

      More details

    Grant type:Competitive

  5. EBウイルスゲノム複製装置形成・成熟の分子基盤の解明

    2017.8

    医学系研究奨励 

      More details

    Grant type:Competitive

  6. 食品中に含まれる化学物質が発がんウイルスEBVの増殖に与える影響の解析

    2016.10 - 2017.3

    医学研究・健康増進活動等助成 

    佐藤好隆

      More details

    Grant type:Competitive

  7. CMV/EBVのウイルス後期遺伝子の転写を抑制する小分子の探索

    2015.8 - 2017.3

    GSKジャパン研究助成 

    佐藤好隆

      More details

    Grant type:Competitive

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 5

  1. Epstein-Barrウイルス蛋白質によるp53の不活化機構の解析

    2007.4 - 2009.3

    科学研究費補助金 

      More details

    Authorship:Principal investigator 

  2. EBウイルスがT/NK細胞内で形成するスーパーエンハンサーの解析

    Grant number:21K15448  2021.4 - 2023.3

    若手研究

    佐藤 好隆

      More details

    Authorship:Principal investigator 

    Grant amount:\4680000 ( Direct Cost: \3600000 、 Indirect Cost:\1080000 )

    Epstein-Barrウイルス(EBV)は、B細胞を自然宿主とする普遍的なウイルスであるが、時にT細胞およびNK細胞にも感染し、節外性NK/T細胞リン パ腫・鼻型、急速進行性NK細胞白血病や慢性活動性EBV感染症などの血液腫瘍の原因となる。これらのEBV 関連T/NK細胞腫瘍は日本をはじめとした東アジアで報告が多く、予後不良で有効な治療法は未だ存在しない。
    本研究では、細胞を特徴付ける転写プロファイルと密接な関係をもつスーパーエンハンサーを解析し、EBV関連T/NK細胞腫瘍に特異的なスーパーエンハンサーを同定する。そして、予後不良なEBV関連T/NK細胞腫瘍の新たな治療法の開発を目指す。

  3. 周囲の環境に応じた感染細胞の運命決定機構の解明

    Grant number:19H04829  2019.4 - 2021.3

    新学術領域研究(研究領域提案型)

    佐藤 好隆

      More details

    Authorship:Principal investigator 

    Grant amount:\6500000 ( Direct Cost: \5000000 、 Indirect Cost:\1500000 )

    本研究は、感染細胞の外(周囲の環境)に主眼をおき、感染細胞自身ではなく、その周囲の環境も潜伏感染の成立・維持に寄与するという新たな原理とその分子基盤の解明を目指す。全人口の90%以上が感染しているEpstein-Barrウイルスを主な研究対象として、周囲の環境が感染細胞の運命決定(潜伏感染を継続するか溶解感染へ移行するかなど)に、どのような影響を及ぼすかを解析する。EBV は、感染者の一部に腫瘍を引き起こすが、ほとんどは不顕性感染状態である。病原性と非病原性が同居するウイルスであり、本研究は従来のウイルス学とネオウイルス学の2つのウイルス学の発展と理解に貢献する。
    ウイルスは効率よく子孫ウイルスを標的細胞に感染させるため、宿主に寄り添って(寄り添うフリをして)、感染に有利な環境になるのを宿主内でじっと待つ(潜伏感染)。そして、宿主を裏切り、ウイルス粒子の産生(溶解感染)を起こす。
    全人口の90%以上が感染しているEpstein-Barrウイルス(EBV)を主な研究対象として、周囲の環境が感染細胞の運命決定(潜伏感染を継続するか溶解感染へ移行するかなど)に、どのような影響を及ぼすかを解析することを目的に本研究計画を進めた。
    RNAseq解析により、EBVの感染初期にウイルス産生に関わる遺伝子群が発現していることが示唆された。しかし、RNAseqは集団での遺伝子発現を捉えるスナップショットに過ぎず、時間分解能が弱いという欠点がある。そこで、組換えウイルスを用いたFate mappingにより、直接的に感染細胞の運命を追えるシステムを開発した。本システムにより、EBVの感染初期にウイルス産生に関わる遺伝子群が発現していることを証明した。さらに、EBV感染のダイナミクスを経時的に追い、EBV感染の広がりを数理モデル化した。本研究で樹立した数理モデルにより、EBV感染の初期ではウイルス粒子産生は起きていないことが改めて確認された。以上より、EBV感染の初期では不完全なウイルス産生感染(abortive lytic infection)をいう中間状態を経由して、潜伏感染の成立に至ることが実証された。
    組換えEBVを使用したFate mappingにより、EBV感染の初期では不完全なウイルス産生感染(abortive lytic infection)をいう中間状態を経由して、潜伏感染の成立に至ることが実証できた。また、EBV感染の広がりを数式で記述することも達成できた。以上の結果は、論文としてまとめて、現在投稿中である。総じて、概ねに計画は進展していると考える。
    一方で、コロナウイルス感染症の影響でウイルス感染細胞の周囲の環境に関するメタボローム解析には遅れが生じはじめており、今後対策を考えていく。
    周囲の影響がウイルス感染に与える影響のフェノタイプは捉えつつある。次年度は、このフェノタイプの責任分子の同定を精力的に進めていきたい。メタボローム解析は新型コロナウイルス感染症の拡大を受けて、共同研究先の人員確保困難で遅れがでている。周囲の影響がウイルス感染に与える影響のフェノタイプを司る分子の同定は薬剤スクリーニングなど別の方法で探索することも模索していきたい。さらに、本研究課題を進めて行く中で想起した環境を介した異種ウイルス間の相互作用についても、本研究課題を発展させながら解析を進めていこうと考えている。領域内の研究者と密に連絡・連携を取りながら、研究を進展させていきたい。

  4. A genome-wide knockout screen identified host factors modulating herpes simplex virus infection

    Grant number:16H06231  2016.4 - 2020.3

    SATO Yoshitaka

      More details

    Authorship:Principal investigator 

    Grant amount:\25220000 ( Direct Cost: \19400000 、 Indirect Cost:\5820000 )

    Herpes simplex virus (HSV) is a common pathogen that causes skin infection as well as fatal encephalitis. HSV is categorized into 2 types: HSV type 1 (HSV-1) and HSV type 2 (HSV-2). Targeting host factors involved in HSV-infection and -propagation is an attractive approach to regulate those viruses. To identify a set of HSV host factors, we carried out a genome wide CRISPR screen. In this study, we established high quality KO library that showed the presentation of over 98% individual sgRNA. We isolated 53 genes for HSV-1, and 21 genes for HSV-2 as responsible host genes for viral infection and propagation. Among these isolated genes, NECTIN-1 and a series of genes involved in heparan sulfate biosynthesis, which are known for HSV viral receptors, were included. The other candidate genes are currently being investigated. Our study may provide new insights into the molecular mechanism of HSV viral entry and of the tropism that differs between HSV-1 and HSV-2.

  5. Research for the mechanism of latency and immortalization of Epstein-Barr virus using haploid cells

    Grant number:16K15525  2016.4 - 2018.3

    Kimura Hiroshi

      More details

    Authorship:Coinvestigator(s) 

    Epstein-Barr virus (EBV) is associated with a variety of intractable infections and malignancies. HAP-1 cells, which have only one genome set, is suitable for genome screening. In this study, we tried screening of host genes to be associated with latency or immortalization of EBV using HAP-1 cells and next generation sequencing. We successfully generated HAP-1/EBV cells, but could not identify any host genes because of the lack in the maintenance of EBV.

Industrial property rights 1

  1. 抗ウイルス薬

    佐藤好隆, 渡辺崇広, 木村宏

     More details

    Application no:2017-250093  Date applied:2017.12

    Country of applicant:Domestic